<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Conferences on Alexander Junge&#39;s website</title>
    <link>https://www.alexanderjunge.net/categories/conferences/</link>
    <description>Recent content in Conferences on Alexander Junge&#39;s website</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-US</language>
    <lastBuildDate>Mon, 26 Mar 2018 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="https://www.alexanderjunge.net/categories/conferences/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Illuminating the Druggable Genome (IDG) phase 2 kick-off</title>
      <link>https://www.alexanderjunge.net/blog/idg2-f2f/</link>
      <pubDate>Mon, 26 Mar 2018 00:00:00 +0000</pubDate>
      
      <guid>https://www.alexanderjunge.net/blog/idg2-f2f/</guid>
      <description>Two weeks ago, I attended the kick-off meeting of phase 2 of the Illuminating the Druggable Genome (IDG) program. A pdf of our poster presented at the meeting is available here.
The IDG program aims to shed light on understudied drug targets - proteins that are members of three protein families commonly targeted by drugs (G-protein coupled receptors, ion channels, protein kinases) that themselves have not attracted much research attention. The IDG Consortium is supported by the NIH’s Common Fund and my postdoctoral research is currently funded by the IDG grant.</description>
    </item>
    
  </channel>
</rss>